Document › Details
Novartis AG. (11/18/15). "Press Release: Regulatory Submission for Sandoz’ Proposed Biosimilar Pegfilgrastim Accepted by the FDA". Holzkirchen.
|Region||United States (USA)|
|Organisation||Sandoz International GmbH|
|Organisation 2||FDA (US Food and Drug Administration)|
|Group||United States (govt)|
|Person||McCamish, Mark (Novartis 201607 Head of Global Biopharma Development at Sandoz)|
Sandoz continues to advance its biosimilars program:
Regulatory submission for Sandoz' proposed biosimilar pegfilgrastim accepted by the FDA
> Sandoz demonstrates commitment to oncology by seeking approval for its proposed biosimilar pegfilgrastim.
> Sandoz believes that the totality of evidence in its submission, including three pivotal clinical studies, will demonstrate that the proposed biosimilar is highly similar to the reference product.
> Proposed biosimilar pegfilgrastim filing is the second of ten regulatory filings planned over the next three years.
Sandoz, a Novartis company and the global leader in biosimilars, announced today that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) under the 351 (k) pathway for its proposed biosimilar to Amgen's US-licensed Neulasta® (pegfilgrastim)* - a recombinant human granulocyte colony-stimulating factor (G-CSF).
Sandoz is seeking approval for the same indication as the reference product. Pegfilgrastim is a prescription medicine used to help reduce the chance of infection due to a low white blood cell count, in patients with cancer (non-myeloid) who receive chemotherapy that can cause fever and a low blood cell count (febrile neutropenia).In the US, the incidence of febrile neutropenia is estimated to be more than 60,000 a year, accounting for nearly eight cases per 1,000 cancer patients. Approximately 1.6 million people per year in the US develop non-myeloid cancer.
"The FDA's acceptance of our regulatory submission for biosimilar pegfilgrastim - our third biosimilar filed in the US - demonstrates our commitment to expanding patient access to biologics in the US" said Mark McCamish, M.D., Ph.D., and Head of Global Biopharmaceutical & Oncology Injectables Development at Sandoz. "If approved, physicians will have another high-quality Sandoz treatment option for patients needing granulocyte colony-stimulating factors" McCamish continued.
Sandoz believes that the totality of evidence in its submission, including three pivotal clinical trials - one pharmacokinetic and pharmacodynamic study in healthy volunteers and two comparative efficacy and safety studies in breast cancer patients - will demonstrate that the proposed biosimilar is highly similar to the reference product and therefore justifies use of biosimilar pegfilgrastim in the reference product's indication.
Sandoz has an unwavering commitment to increasing patient access to high-quality, life-enhancing biosimilars. It is the pioneer and global market leader and currently markets three biosimilars. On 3 September, 2015 Sandoz launched the first biosimilar in the United States and recently had its regulatory submission for proposed biosimilar etanercept accepted by the FDA. Sandoz has a leading pipeline with several biosimilars across the various stages of development including five programs in Phase III clinical trials or registration preparation. The company plans to make ten planned regulatory filings over the next three years. As part of the Novartis Group, Sandoz is well-positioned to lead the biosimilars industry based on its experience and capabilities in development, manufacturing and commercialization.
* Neulasta is a registered trademark of Amgen Inc.
The foregoing release contains forward-looking statements that can be identified by words such as "proposed," "commitment," "seeking," "believes," "will," "planned," "potentially," "pipeline," "plans," or similar terms, or by express or implied discussions regarding potential marketing approvals for biosimilar pegfilgrastim, or regarding potential future revenues from biosimilar pegfilgrastim. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that biosimilar pegfilgrastim will be approved for sale in the United States, or at any particular time. Neither can there be any guarantee that biosimilar pegfilgrastim will be submitted or approved for sale in any additional markets, or at any particular time. Nor can there be any guarantee that biosimilar pegfilgrastim will be commercially successful in the future. In particular, management's expectations regarding biosimilar pegfilgrastim could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; the uncertainties inherent in research and development, including unexpected clinical trial results and additional analysis of existing clinical data; competition in general, including potential approval of additional versions of biosimilar pegfilgrastim; global trends toward health care cost containment, including government, industry and general public pricing pressures; unexpected litigation outcomes, including intellectual property disputes or other legal efforts to prevent or limit Sandoz from selling biosimilar pegfilgrastim; the particular prescribing preferences of physicians and patients; unexpected safety issues; unexpected manufacturing or quality issues; general economic and industry conditions, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
Sandoz, a Novartis company, is a global leader in generic pharmaceuticals and biosimilars, driving sustainable access to high-quality healthcare. Sandoz employs more than 26,000 people worldwide and supplies a broad range of affordable, primarily off-patent products to patients and customers around the globe. The Sandoz portfolio comprises approximately 1,100 molecules, which accounted for 2014 sales of USD 9.6 billion. Sandoz is headquartered in Holzkirchen, in Germany's Greater Munich area. The company holds leading global positions in biosimilars as well as in generic anti-infectives, ophthalmics and transplantation medicines.
 Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer. 2005;103(9):1916
 American Cancer Society. Cancer Facts & Figures 2015. http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf (link is external) (Last accessed 19 October 2015)
# # #
For further information:
Novartis Global Media Relations
Sandoz Global Communications+49 (0) 162 429 7971
Sandoz US Communications
Novartis Investor Relations:
Central phone: +41 61 324 7944 North America:
Samir Shah +41 61 324 7944 Richard Pulik +1 212 830 2448
Pierre-Michel Bringer +41 61 324 1065 Sloan Pavsner +1 212 830 2417
Thomas Hungerbuehler +41 61 324 8425
Isabella Zinck +41 61 324 7188
Record changed: 2016-07-16
More documents for Novartis (Group)
-  MorphoSys AG. (1/12/17). "Press Release: MorphoSys Partner to Start Phase 2 Trial with Bimagrumab in Obese Patients with Type 2 Diabetes". Planegg....
-  MorphoSys AG. (1/5/17). "Press Release: Dr. Malte Peters to Become New Chief Development Officer of MorphoSys AG". Planegg....
-  Protagen AG. (12/20/16). "Press Release: Protagen AG Successfully Joined Forces with Novartis to Support Clinical Development of a Novel Compound in an Autoimmune Indication"....
-  Novartis AG. (12/16/16). "Press Release: Novartis Bolsters Innovative Dermatology Portfolio through Acquisition of Ziarco Group Limited". Basel....
-  Novartis AG. (12/12/16). "Press Release: Novartis Provides Update on Pegpleranib Phase III Clinical Trial Program in Patients with Neovascular Age-related Macular Degeneration (nAMD or wet AMD)". Basel....
-  Novartis AG. (12/3/16). "Press Release: Novartis SEG101 (Crizanlizumab, formerly SelG1) Significantly Reduces Frequency of Sickle Cell Pain Crises in Phase II Study". Basel....
-  Novartis AG. (11/21/16). "Press Release: Novartis Acquires Selexys Pharmaceuticals Corporation and SelG1 Antibody for Reduction of Pain Crises in Sickle Cell Disease (SCD)". Basel....
-  Novartis AG. (11/18/16). "Press Release: Innovative Study with Three Treatment Switches Confirms Sandoz Biosimilar Etanercept Has Equivalent Efficacy to Originator". Holzkirchen....
-  TxCell S.A.. (10/13/16). "Press Release: TxCell Appoints Dr. Li Zhou as Vice President Cell Engineering to Lead Its CAR-Treg Programs". Valbonne....
-  GlaxoSmithKline plc. (9/29/16). "Press Release: GlaxoSmithKline plc Appoints Brian McNamara as CEO of GSK Consumer Healthcare". London....
To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to firstname.lastname@example.org and simply fill the subject line with the word »LSG newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)